Spevigo® Intravenous (spesolimab-sbzo intravenous infusion)

Covered: Spevigo (spesolimab‑sbzo) IV is authorized only for FDA‑approved generalized pustular psoriasis (GPP) flares in patients ≥12 years and ≥40 kg and is excluded for patients <12 years, <40 kg, non–moderate‑to‑severe flares, or if GPPGA/BSA/pustulation criteria are not met. Key requirements: initial approval requires moderate‑to‑severe flare with GPPGA total ≥3 and pustulation subscore ≥2, new/worsening pustules affecting ≥5% BSA, dermatologist prescription/consultation, dosing of 900 mg IV once (option for a second 900 mg at 1 week), maximum two doses per flare, ≥12 weeks between flares, 3‑month approval duration, and reauthorization requires a ≥2‑point increase in GPPGA total and pustulation subscore ≥2.

"Treatment of generalized pustular psoriasis flares."

Sign up to see full coverage criteria, indications, and limitations.